MFN.se
Press release/News aggregator
On mfn.se, we offer streamed and historical press releases and for all listed companies in the Nordics, regardless of provider. MFN is the optimal website for those who want to stay quickly updated on market events. Source
Actions
Media Outlet details
| Scope | Trade/B2B |
|---|---|
| Language | Danish, English, Finnish, Norwegian, Swedish |
| Country | Sweden |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesRess Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments Nybrogade 12 DK-1203 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 15 July 2026 Corporate Announcement 25/2026 Ress Life Investments A/S publishes Net Asset Value (NAV). Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 30 June 2026. NAV per share in USD: 2722.35 The performance during June is -0.38% in USD. The year-to-date net performance is 3.17% in USD.
Desert Control AS: Updated key information relating to the proposed fully underwritten rights issue
15.07.2026 Desert Control AS: Updated key information relating to the proposed fully underwritten rights issue NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
Desert Control AS: Updated proposed resolutions for the EGM for the fully underwritten rights issue
15.07.2026 Desert Control AS: Updated proposed resolutions for the EGM for the fully underwritten rights issue NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
Senzime and Philips Medical Systems enter development and commercialization partnership
Uppsala, Sweden, July 15, 2026 – Senzime AB announced today that it has entered into a long-term agreement with Philips Electronics Nederland, B.V. through Philips Hospital Patient Monitoring business, a global leader in patient monitoring systems. The collaboration will explore and develop potential future solutions leveraging the companies’ respective proprietary technologies.
Senzime och Philips Medical Systems ingår långsiktigt partnerskap för utveckling och kommersialisering
Uppsala 15 juli, 2026 - Senzime AB meddelade idag att bolaget ingått ett långsiktigt avtal med Philips Electronics Nederland B.V., genom affärsområdet Philips Hospital Patient Monitoring, en global ledare inom patientövervakningssystem. Samarbetet syftar till att utveckla och kommersialisera nya produkter baserade på bolagens respektive proprietära teknologier. Lösningarna kommer rikta sig mot marknadssegment som kompletterar Senzimes befintliga produktportfölj och försäljningskanaler.
Svedbergs Group: EBITA margin set to recover in the UK next year – Q2 review
DNB Carnegie has published a new commissioned research report on Svedbergs Group. To access the full report and subscribe to future updates, visit https://access.dnbcarnegie.com/companies/1460 This is a press release from DNB Carnegie. For information about DNB Carnegie commissioned research, see https://access.dnbcarnegie.com/, or contact our commissioned research team at cr@carnegie.se. DNB Carnegie is the leading and independent Nordic investment and private bank.
Alimak Group förvärvar Pro-Bel och tar ytterligare ett steg i exekveringen av New Heights-strategin
Sammanfattning av förvärvet: Pro-Bel genererade 69 MCAD (cirka 473 MSEK) i omsättning och 24 MCAD (cirka 165 MSEK) i justerad EBITA under den senaste tolvmånadersperioden som avslutades i april 2026, motsvarande en justerad EBITA-marginal om 34,6%. Transaktionen värderar Pro-Bel till ett företagsvärde (enterprise value) om 200 MCAD (cirka 1 370 MSEK) på kassa- och skuldfri basis, motsvarande en justerad EBITA-multipel om 8,3x baserat på utfallet för räkenskapsåret som avslutades i april 2026.
Alimak Group acquires Pro-Bel and takes another step in the Groupâs New Heights strategy
Summary of the acquisition: ProâBel generated MCAD 69 (approximately MSEK 473) in revenue and MCAD 24 (approximately MSEK 165) in adjusted EBITA for the latest twelve-month period ending April 2026, corresponding to an adjusted EBITA margin of 34.6%. The transaction values ProâBel at an enterprise value of MCAD 200 (approximately MSEK 1,370), on a cash- and debt-free basis, corresponding to an adjusted EBITA multiple of 8.3x based on fiscal year ending April 2026 actuals.
Swedish Orphan Biovitrum AB: The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under an incentive programme
The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026, resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme for permanent employees (the All Employee Programme) resolved by the Annual General Meeting - on a directed share issue of no more than 223,677 redeemable and convertible class C shares.
Swedish Orphan Biovitrum AB: Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram
Årsstämman i Swedish Orphan Biovitrum AB (publ) (Sobi®) den 6 maj 2026 beslutade - i syfte att säkerställa att bolaget kan fullgöra sina åtaganden enligt det av årsstämman beslutade långsiktiga incitamentsprogrammet för fast anställda (Personalprogrammet) - om en riktad nyemission av högst 223 677 inlösen- och omvandlingsbara C-aktier.